Hematology TimesAppalachia has higher cancer incidence than rest of USJanuary 28, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaRelated IssuesHodgkin Lymphoma
Hematology NewsAcalabrutinib yields 95% overall response in relapsed CLLJanuary 27, 2016CLLLeukemia, Myelodysplasia, Transplantation
Hematology TimesCompounds could treat leukemia, lymphomaJanuary 27, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology TimesLeukemia death rates expected to fall in EUJanuary 27, 2016Leukemia, Myelodysplasia, Transplantation
Hematology NewsGemtuzumab ozogamicin boosts overall survival in older AML patientsJanuary 25, 2016AMLLeukemia, Myelodysplasia, Transplantation
Hematology NewsCAR T-cells induce remissions, avoid GVHD in relapsed B-cell malignanciesJanuary 25, 2016ALLCellular TherapyLeukemia, Myelodysplasia, Transplantation
Oncology PracticeCD30 identified as novel target in systemic mastocytosisJanuary 25, 2016Leukemia, Myelodysplasia, Transplantation
Hematology TimesNew insight into CLL developmentJanuary 25, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesFruit fly findings may have implications for leukemia, other cancersJanuary 24, 2016Leukemia, Myelodysplasia, Transplantation
Hematology NewsMinimal residual disease a powerful prognostic factor in AMLJanuary 23, 2016AMLLeukemia, Myelodysplasia, Transplantation
Hematology TimesMRD test can predict AML relapseJanuary 22, 2016Leukemia, Myelodysplasia, TransplantationAML
Hematology TimesFertility concerns of AYA cancer survivorsJanuary 22, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersRelated Issues
Hematology TimesEnd-of-life cancer care by countryJanuary 21, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaRelated Issues
Hematology TimesProtein may be therapeutic target for AMLJanuary 21, 2016Leukemia, Myelodysplasia, TransplantationAML
Hematology TimesDrug granted another breakthrough designation for CLLJanuary 21, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
